Developer docs
API playgroundTry for free, no card

Search company profiles

NeoChord

Full company profile

uuid0002o5b

Namestring
NeoChord
Legal namestring
NeoChord, Inc.
Websiteurl
neochord.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

NeoChord, Inc. is a privately held medical device company founded in 2007 and headquartered in Maple Grove, Minnesota. The company develops devices that enable mitral valve repair to be performed on a beating heart, addressing degenerative mitral valve regurgitation (MR) without requiring cardiopulmonary bypass or open sternotomy. Its flagship product, the NeoChord Artificial Chordae Delivery System (Model DS1000), is a transapical, echo-guided system that delivers artificial chordae tendineae to re-suspend prolapsed mitral valve leaflets under real-time transesophageal echocardiography (TEE) guidance. The DS1000 received CE market clearance in December 2012 and carries an MR Conditional designation for 1.5T and 3.0T MRI scanning. In the United States the device remains investigational, with FDA IDE approval supporting ongoing clinical work including the RECHORD randomized trial.

The company is advancing a second-generation transcatheter platform, the NeoChord NeXuS System, which uses a transfemoral/transseptal approach for a less invasive procedure than the transapical DS1000. NeXuS completed first-in-human use in October 2021 with positive 30-day results, received FDA approval for an Early Feasibility Study, and won the CRT 2022 Best Innovation Competition. Supporting programs include ConsultConnect and ConnectCARD for clinical consultation, plus the AcChord post-market registry. The portfolio is anchored by registered trademarks (NEOCHORD, DS1000, RECHORD, NEOCHORD CONSULTCONNECT, CONNECTCARD, ACCHORD, ULTRACHORD) and a patent estate associated with the leadership team. By October 2016, more than 500 patients had been treated globally with DS1000, with follow-up data on 127 patients out to two years presented at EACTS.

NeoChord sells Class III medical hardware directly to hospitals and cardiac surgery centers through an enterprise field sales motion, supported by key opinion leader engagement, clinical trial programs, and presence at medical conferences. The company holds NUB Status 1 in Germany, providing favorable reimbursement conditions for the procedure. Geographic reach spans the United States, Europe (Germany, Poland), and Asia (China, with the first procedures completed in September 2018). The company has 11–50 employees, has raised over $90 million across multiple financing rounds including a $32 million Series D, and operates under CEO Todd Berg, who joined in September 2023 after prior roles as founder/CEO of Torax Medical (acquired by Johnson & Johnson) and CEO of Metavention.

Short descriptiontext

NeoChord is a privately held medical device company developing beating-heart mitral valve repair systems. Its CE-marked DS1000 and investigational NeXuS transcatheter platform deliver artificial chordae under echo guidance to treat degenerative mitral regurgitation at cardiac surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMaple Grove, United States
HQ citystring
Maple Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mitral valve repair, artificial chordae delivery, beating heart surgery, structural heart devices, transcatheter chordal repair
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Mitral Valve Repair Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

NeoChord generates revenue through the sale of its NeoChord Artificial Chordae Delivery System (DS1000) and related products to hospitals and cardiac surgery centers. The company has received CE market clearance (December 2012) and FDA IDE approval for clinical trials in the US.

neochord.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1NeoChord DS1000
Description

Artificial Chordae Delivery System for mitral valve repair

neochord.com
+4 more records
Core offering1 text field

NeoChord develops and sells Class III medical devices for beating heart mitral valve repair, primarily the NeoChord Artificial Chordae Delivery System (DS1000), a transapical, echo-guided system that implants artificial chordae tendineae to treat degenerative mitral valve regurgitation without cardiopulmonary bypass. The company is also developing the next-generation NeXuS transcatheter transseptal chordal repair system for a less invasive approach, and operates the ConsultConnect clinical consultation program to support implanting physicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 500+ patients treated globally with DS1000 system
+2 more records
Product overview1 text field

NeoChord is a medical technology company with a focused product portfolio centered on mitral valve repair. The core offerings consist of two generations of chordal repair systems: the established DS1000 (transapical approach, CE marked in 2012) for beating heart mitral valve repair, and the newer transcatheter NeXuS System (transseptal approach, investigational) for less invasive procedures. Both products restore mitral valve function by implanting artificial chordae to support prolapsing valve leaflets. The portfolio also includes the ConsultConnect service program for clinical consultation support.

Product and service3 records
1NeoChord Artificial Chordae Delivery System (DS1000)
CategoryMitral Valve Repair Medical Device
Description

A transapical, echo-guided Class III medical device that delivers artificial chordae tendineae to repair degenerative mitral valve regurgitation on a beating heart without cardiopulmonary bypass. Indicated for patients with moderate to severe degenerative mitral valve regurgitation caused by elongated or ruptured chordae tendineae, and sold to hospitals and cardiac surgery centers. CE marked since December 2012; in the U.S. limited to investigational use under FDA IDE.

2NeoChord NeXuS Transcatheter Transseptal Mitral Chordal Repair System
CategoryMitral Valve Repair Medical Device
Description

A transcatheter, transseptal catheter-based mitral chordal repair system designed to enable a less invasive approach to mitral valve repair compared to the transapical DS1000. The system received FDA approval for an Early Feasibility Study in the U.S. with Dr. Martin B. Leon serving as Executive Chair, and achieved first-in-human clinical results in October 2021.

3NeoChord ConsultConnect (including ConnectCARD)
CategoryClinical Support Service
Description

A medical consultation and clinical support service program related to delivery of artificial chordae tendineae for treatment of mitral insufficiency, providing healthcare professionals with access to NeoChord's clinical support, training, and expertise for the DS1000 and NeXuS procedures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Skirball Center for Innovation at the Cardiovascular Research Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

NeoChord announced a research collaboration with the Skirball Center for Innovation at the Cardiovascular Research Foundation in January 2018. This collaboration supports the development and validation of NeoChord's mitral valve repair technologies through rigorous clinical research programs.

neochord.com
Market position
Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeoChord

Mitral Valve Repair Medical Devicesneochord.com

NeoChord is a privately held medical device company developing beating-heart mitral valve repair systems. Its CE-marked DS1000 and investigational NeXuS transcatheter platform deliver artificial chordae under echo guidance to treat degenerative mitral regurgitation at cardiac surgery centers.

What NeoChord does

NeoChord, Inc. is a privately held medical device company founded in 2007 and headquartered in Maple Grove, Minnesota. The company develops devices that enable mitral valve repair to be performed on a beating heart, addressing degenerative mitral valve regurgitation (MR) without requiring cardiopulmonary bypass or open sternotomy. Its flagship product, the NeoChord Artificial Chordae Delivery System (Model DS1000), is a transapical, echo-guided system that delivers artificial chordae tendineae to re-suspend prolapsed mitral valve leaflets under real-time transesophageal echocardiography (TEE) guidance. The DS1000 received CE market clearance in December 2012 and carries an MR Conditional designation for 1.5T and 3.0T MRI scanning. In the United States the device remains investigational, with FDA IDE approval supporting ongoing clinical work including the RECHORD randomized trial.

The company is advancing a second-generation transcatheter platform, the NeoChord NeXuS System, which uses a transfemoral/transseptal approach for a less invasive procedure than the transapical DS1000. NeXuS completed first-in-human use in October 2021 with positive 30-day results, received FDA approval for an Early Feasibility Study, and won the CRT 2022 Best Innovation Competition. Supporting programs include ConsultConnect and ConnectCARD for clinical consultation, plus the AcChord post-market registry. The portfolio is anchored by registered trademarks (NEOCHORD, DS1000, RECHORD, NEOCHORD CONSULTCONNECT, CONNECTCARD, ACCHORD, ULTRACHORD) and a patent estate associated with the leadership team. By October 2016, more than 500 patients had been treated globally with DS1000, with follow-up data on 127 patients out to two years presented at EACTS.

NeoChord sells Class III medical hardware directly to hospitals and cardiac surgery centers through an enterprise field sales motion, supported by key opinion leader engagement, clinical trial programs, and presence at medical conferences. The company holds NUB Status 1 in Germany, providing favorable reimbursement conditions for the procedure. Geographic reach spans the United States, Europe (Germany, Poland), and Asia (China, with the first procedures completed in September 2018). The company has 11–50 employees, has raised over $90 million across multiple financing rounds including a $32 million Series D, and operates under CEO Todd Berg, who joined in September 2023 after prior roles as founder/CEO of Torax Medical (acquired by Johnson & Johnson) and CEO of Metavention.

NeoChord firmographics

Firmographics
Name
NeoChord
Legal name
NeoChord, Inc.
Website
https://neochord.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
NeoChord is a privately held medical device company developing beating-heart mitral valve repair systems. Its CE-marked DS1000 and investigational NeXuS transcatheter platform deliver artificial chordae under echo guidance to treat degenerative mitral regurgitation at cardiac surgery centers.
Ownership category
akta.pro rank

NeoChord industry classification

Industry
Product category
Mitral Valve Repair Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Mitral valve repair
  • Artificial chordae delivery
  • Beating heart surgery
  • Structural heart devices
  • Transcatheter chordal repair

Where NeoChord is headquartered

Location

Headquarters

HQ city
Maple Grove
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeoChord business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: NeoChord generates revenue through the sale of its NeoChord Artificial Chordae Delivery System (DS1000) and related products to hospitals and cardiac surgery centers. The company has received CE market clearance (December 2012) and FDA IDE approval for clinical trials in the US.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

NeoChord product offering

Product offering

Core offering

NeoChord develops and sells Class III medical devices for beating heart mitral valve repair, primarily the NeoChord Artificial Chordae Delivery System (DS1000), a transapical, echo-guided system that implants artificial chordae tendineae to treat degenerative mitral valve regurgitation without cardiopulmonary bypass. The company is also developing the next-generation NeXuS transcatheter transseptal chordal repair system for a less invasive approach, and operates the ConsultConnect clinical consultation program to support implanting physicians.

Product overview

NeoChord is a medical technology company with a focused product portfolio centered on mitral valve repair. The core offerings consist of two generations of chordal repair systems: the established DS1000 (transapical approach, CE marked in 2012) for beating heart mitral valve repair, and the newer transcatheter NeXuS System (transseptal approach, investigational) for less invasive procedures. Both products restore mitral valve function by implanting artificial chordae to support prolapsing valve leaflets. The portfolio also includes the ConsultConnect service program for clinical consultation support.

Differentiator

Problem solved

Functional benefit

Brands

  • NeoChord DS1000: Artificial Chordae Delivery System for mitral valve repair
  • NeoChord NeXuS
  • NeoChord ConsultConnect
  • ConnectCARD
  • RECHORD

Products and services

  • NeoChord Artificial Chordae Delivery System (DS1000) A transapical, echo-guided Class III medical device that delivers artificial chordae tendineae to repair degenerative mitral valve regurgitation on a beating heart without cardiopulmonary bypass. Indicated for patients with moderate to severe degenerative mitral valve regurgitation caused by elongated or ruptured chordae tendineae, and sold to hospitals and cardiac surgery centers. CE marked since December 2012; in the U.S. limited to investigational use under FDA IDE.
  • NeoChord NeXuS Transcatheter Transseptal Mitral Chordal Repair System A transcatheter, transseptal catheter-based mitral chordal repair system designed to enable a less invasive approach to mitral valve repair compared to the transapical DS1000. The system received FDA approval for an Early Feasibility Study in the U.S. with Dr. Martin B. Leon serving as Executive Chair, and achieved first-in-human clinical results in October 2021.
  • NeoChord ConsultConnect (including ConnectCARD) A medical consultation and clinical support service program related to delivery of artificial chordae tendineae for treatment of mitral insufficiency, providing healthcare professionals with access to NeoChord's clinical support, training, and expertise for the DS1000 and NeXuS procedures.

Quantifiable outcome

  • 500+ patients treated globally with DS1000 system
  • +2 more outcomes

Companies that use NeoChord

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

NeoChord technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NeoChord partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Skirball Center for Innovation at the Cardiovascular Research FoundationcoreStrategic or Co-development Partner · 1 January 2018NeoChord announced a research collaboration with the Skirball Center for Innovation at the Cardiovascular Research Foundation in January 2018. This collaboration supports the development and validation of NeoChord's mitral valve repair technologies through rigorous clinical research programs.

Scale indicators5 records

NeoChord competitors and assessment

Company assessment

Market position

Key highlights7 records

Customer concentration

NeoChord social profiles

Digital presence

NeoChord compliance and trust

Trust signal

Compliance2 records

NeoChord financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeoChord leadership team

Management profile

Number of profiles

Profiles8 records

NeoChord funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeoChord M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoChord

What does NeoChord do?

NeoChord develops and sells Class III medical devices for beating heart mitral valve repair, primarily the NeoChord Artificial Chordae Delivery System (DS1000), a transapical, echo-guided system that implants artificial chordae tendineae to treat degenerative mitral valve regurgitation without cardiopulmonary bypass. The company is also developing the next-generation NeXuS transcatheter transseptal chordal repair system for a less invasive approach, and operates the ConsultConnect clinical consultation program to support implanting physicians.

Is NeoChord a public or private company?

NeoChord is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeoChord founded?

NeoChord was founded in 2007. It employs 11 to 50 people.

Where is NeoChord based?

NeoChord is headquartered in Maple Grove, United States, in the North America region.

How does NeoChord make money?

One revenue line is on record: medical Device Sales.

Does NeoChord have an API?

No public API is recorded for NeoChord.

What industry is NeoChord in?

NeoChord's product category is Mitral Valve Repair Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MassDeviceMitral valve repair company NeoChord has a new CEONeoChord appointed Todd Berg as its new CEO to oversee its mitral valve repair programs. NeoChord's DS1000 system holds commercial authorization in Europe, while its NeXus system is currently in feasibility clinical trials. Berg brings over 30 years of medtech experience, previously serving as CEO of Metavention and Torax Medical.PR NewswireNeoChord, Inc. nomme un nouveau PDG pour mener les efforts de commercialisation et étudier un nouveau traitement de première intention pour la régurgitation mitraleNeoChord, Inc., a Minneapolis-based private medical technology company, appointed Todd Berg as its new CEO to oversee clinical and commercialization programs for mitral valve chord repair. Berg brings over 30 years of medical technology experience and more than 100 US patents, having previously led Metavention and Torax Medical, which was acquired by Ethicon (Johnson & Johnson). The company aims to develop a first-line treatment for mitral regurgitation, with its transapical DS1000 system already commercialized in Europe and over 5,000 neochords placed in more than 2,000 patients, while its transseptal NeXus system remains in clinical feasibility trials.PR NewswireNeoChord, Inc. nombra un nuevo consejero delegado para liderar los esfuerzos de comercializaciónNeoChord, Inc., a Minneapolis-based private medical technology company and world leader in artificial chordae for treating mitral valve regurgitation, appointed Todd Berg as its new CEO to oversee clinical and commercial programs for its minimally invasive repair technologies. Berg brings over 30 years of experience developing and commercializing new medical therapies, having previously served as CEO of Metavention and Torax Medical (acquired by Ethicon, a division of Johnson & Johnson). The appointment aims to advance the company's existing transapical repair products while exploring the development of a first-line therapy for early-stage mitral valve disease, addressing a significant treatment gap where fewer than 3% of eligible patients currently receive appropriate care.PR NewswireNeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve RegurgitationNeoChord, a Minneapolis-based medical technology company specializing in mitral valve regurgitation treatment, appointed Todd Berg as its new Chief Executive Officer to lead clinical and commercial programs. Berg brings over 30 years of experience in medical technology, having previously led Metavention and Torax Medical, which was acquired by Ethicon, a division of Johnson & Johnson. The company aims to develop a first-line therapy for early-stage mitral valve disease, addressing a clinical gap where less than 3% of patients with severe mitral regurgitation currently receive treatment due to the invasiveness of traditional open-heart surgery.PR NewswireNeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve RegurgitationNeoChord, a privately held medical technology company specializing in mitral valve regurgitation treatment, appointed Todd Berg as Chief Executive Officer to lead its clinical and commercial programs. Berg brings over 30 years of medical technology experience, having previously led Torax Medical, which was acquired by Johnson & Johnson's Ethicon division, and Metavention. The company aims to develop a first-line therapy for early-stage mitral valve disease using its transseptal approach to complement its commercially successful transapical repair products.JaccFirst-in-Human Transseptal Transcatheter Mitral Chordal RepairA 55-year-old high-risk patient underwent the first-in-human use of the NeoChord NeXuS system to repair severe mitral valve regurgitation via a transcatheter approach. The procedure successfully restored normal mitral valve function with trace residual regurgitation, and the patient showed sustained clinical improvement at the three-month follow-up. This case demonstrates the feasibility of the technology as a viable alternative for patients unsuitable for open heart surgery.TermediaPełny tekst: Early echocardiographic results of transapical off-pump mitral valve repair with the NeoChord DS1000 device in patients with severe mitral regurgitation due to posterior leaflet prolapse:A study published in 2019 reports on the first experiences using the NeoChord DS1000 device for transapical off-pump mitral valve repair in Poland. The research focuses on early echocardiographic results for patients suffering from severe mitral regurgitation caused by posterior leaflet prolapse. This represents an initial clinical evaluation of this specific medical intervention within the Polish healthcare context.PulmonaryhypertensionnewsRisk to PH Patients May be Lower with Mitral Valve Surgery Being...The ReChord clinical trial is testing NeoChord, a minimally invasive surgical procedure for mitral valve regurgitation that avoids open-heart surgery. The study involves 585 participants across the U.S. and compares the new catheter-based technique against standard surgical repair to evaluate safety and efficacy. Early data suggests the procedure offers faster recovery and fewer complications for patients with pulmonary hypertension.GlobeNewswireAndrew ElBardissi, M.D. Named to NeoChord Board of DirectorsNeoChord, Inc. appointed Andrew ElBardissi, M.D. to its Board of Directors, effective immediately, replacing Avi Kometz. ElBardissi brings experience in cardiothoracic surgery and early-stage medical technology, and the company is advancing its US clinical trial.